Meeting
2016 Gastrointestinal Cancers Symposium
Evaluation of triptolide pro-drug (Minnelide) as an anti-stromal and anti-tumoral therapeutic option for pancreatic cancer.
Authors
Sulagna Banerjee
University of Minnesota, Minneapolis, MN
Sulagna Banerjee , Shrey Modi , Xianda Zhao , Vikas Dudeja , Ashok Saluja
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 262)
DOI
10.1200/jco.2016.34.4_suppl.262
Abstract #
262
Poster Bd #
D8
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Interim data: Phase I/IIa study of EGFR-targeted EDV nanocells carrying cytotoxic drug PNU-159682 (E-EDV-D682) with immunomodulatory adjuvant EDVs carrying α-galactosyl ceramide (EDV-GC) in patients with recurrent, metastatic pancreatic cancer.
First Author: Joanne Lundy
Poster
2024 ASCO Annual Meeting
The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.
First Author: Shanshan Jin
Poster
2023 ASCO Annual Meeting
Comprehensive nationwide study on the prescription of experimental anticancer therapies for compassionate use in children and adolescents in France.
First Author: Pablo Berlanga
Poster
2017 Gastrointestinal Cancers Symposium
Evaluation of efficacy of oral administration of pro-drug of triptolide against pancreatic cancer.
First Author: Vikas Dudeja